Products and Research
Develop innovative drugs to safeguard human health
Products
- M701（EpCAM×CD3 BsAb ）
- Y101D（PD-L1×TGF-β BsAb ）
- Y150（CD38×CD3 BsAb）
- Y2019（RBD-dimer Subunit SARS-CoV-2 Vaccine）
- M802（HER2×CD3 BsAb）
- Y400 （VEGFxANG2 BsAb）
M701（EpCAM×CD3 BsAb ）
Product Features and Advantages
- Mainly used for palliative care primarily for the treatment of malignant ascites（MA）and Malignant pleural effusion（MPE）derived from EpCAM-positive cancer；
- Catumaxomab with the same targets had been used clinically for MA,and the efficacy was obvious ;
- A Phase II clinical trial of M701 in treating malignant ascites(MA) and a Phase Ib/II clinical trial of M701 in treating malignant pleural effusion(MPE) is currently conducting.
Y101D（PD-L1×TGF-β BsAb ）
Product Features and Advantages
- Mainly used for the treatment of a variety of solid tumors；
- Anti-TGF-β modulates tumor microenvironment (TME) and enhances immune efficacy effectively；
- The combination with chemotherapy drugs enhances the anti-tumor efficacy；
- The only PD-L1 × TGF-β symmetric tetravalent BsAb that has entered into clinical development globally;
- The IND approvals by the National Medical Products Administration (NMPA) for a Phase Ib/II clinical trial of Y101D in combination with chemotherapy for the treatment of pancreatic cancer have been obtained.
Y150（CD38×CD3 BsAb）
Product Features and Advantages
- Mainly used for the treatment of relapsed/refractory multiple myeloma (rrMM)；
- There were 22 and 9 CD38 targeted antibody drug candidates or fusion proteins for the treatment of MM under clinical development globally(excluding China) and in China,respectively；
- The only CD38-targeting and T cell-engaging BsAb that has entered into clinical development in China.
Y2019（RBD-dimer Subunit SARS-CoV-2 Vaccine）
Product Features and Advantages
- Stable dimeric structure and strong immunogenicity；
- Does not contain any active virus and thus possesses a lower disease-inducing risk；
- Being developed in cooperation with the Wuhan Institute of Virology, Chinese Academy of Sciences.
M802（HER2×CD3 BsAb）
Product Features and Advantages
- Mainly used for the treatment of HER2-positive solid tumors；
- Data obtained from the completed Phase I clinical trial indicates general safety and good tolerability；
Y400 （VEGFxANG2 BsAb）
Product Features and Advantages
- Mainly used for wet age-related macular degeneration, with 3.9 million patients in China in 2021 statistically and approximately 20 million patients in China and huge market；
- Dual blockade of VEGF and ANG2, providing a stronger therapeutic mechanism；
- Ultra-high concentration formulation of 140mg/ml for intravitreal injection；
- On July 26, 2022, YZYBIO entered into an asset transfer agreement with Shenzhen Kangzhe Vision Pharmaceutical Development Co.,Ltd. (深圳市康哲维盛医药发展有限责任公司)(“CMS Vision”), to transfer all the rights and assets relating to Y400 to CMS Vision.
Patient Recruitment
Products
Indications
Name of the Trial
Phone：
027-82668988
E-Mail：info@yzybio.com
Address：Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China
Share
